Pharmaceutical Development of a Parenteral Formulation of Conivaptan Hydrochloride

References

1. 1.↵
   1. Chagan L.

   Conivaptan HCL for injection (Vaprisol): a vasopressin antagonist for the management of euvolemic hyponatremia. Pharmacy and Therapeutics 2007, 32 (3), 140–150.

   OpenUrl
2. 2.↵
   Astellas news release. FDA approves Astellas' vaprisol for the treatment of euvolemic hyponatremia. January 4, 2006.
3. 3.↵
   1. Gribbon P.,
   2. Sewing A.

   High-throughput drug discovery: what can we expect from HTS. Drug Discov. Today 2005, 10 (1), 17–22.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Sweetana S.,
   2. Akers M. J.

   Solubility principles and practices for parenteral drugs dosage form development. PDA J. Pharm. Sci. Technol. 1996, 50 (5), 330–342.

   OpenUrlFREE Full Text
5. 5.↵
   1. Nema S.,
   2. Washkuhn R. J.,
   3. Brendel R. J.

   Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 1997, 51 (4), 166–171.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Boddapato S.,
   2. Butler L. D.,
   3. Im S.,
   4. Deluca P. P.

   Identification of subvisible barium sulfate crystals in parenteral solutions. J. Pharm Sci. 1980, 69 (5), 608–610.

   OpenUrlPubMed
7. 7.↵
   1. Borchert S. J.,
   2. Abe A.,
   3. Aldrich D. S.,
   4. Fox L. E.,
   5. Freeman J. E.,
   6. White R. D.

   Particulate matter in parenteral products: a review. J. Parenter. Sci. Technol. 1986, 40 (5), 212–241.

   OpenUrlPubMed
8. 8.↵
   1. Yuan L.,
   2. Visor G. C.

   Characterization of metal-ion-nucleotide based particulate matter in solution of 9-[2-(Phosphonomethoxy)Ethyl]Adenine (PMEA). PDA J. Pharm. Sci. Technol. 1997, 51 (1), 30–35.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Stephens D.,
   2. Bares D.,
   3. Robinson D.,
   4. Pec E.

   Determination of amylose/particulate relationship in hydroxyethylstarch. PDA J. Pharm. Sci. Technol. 1999, 53 (4), 181–185.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Alvarez Núñez F. A.,
    2. Yalkowsky S. H.

    Solubilization of diazepam. PDA J. Pharm. Sci. Technol. 1998, 52 (1), 33–36.

    OpenUrlPubMed
11. 11.↵
    1. Rubino J. T.,
    2. Blanchard J.,
    3. Yalkowsky S. H.

    Solubilization by cosolvents II: Phenytoin in binary and ternary solvent. J. Parenter. Sci. Technol. 1984, 38 (6), 215–221.

    OpenUrlPubMed
12. 12.↵
    1. Yalkowsky S. H.

    Solubility and Solubilization in Aqueous Media; American Chemical Society; Washington, D.C., 1999; pp 190, 204, 205, 424, 425, 429.
13. 13.↵
    1. Kaneko T.

    An ion exchange model of glass leaching. J. Mater. Sci. Lett. 1985, 4 (5), 631–634.

    OpenUrl
14. 14.↵
    1. Ennis R. D.,
    2. Pritchard R.,
    3. Nakamura C.,
    4. Coulon M.,
    5. Yang T.,
    6. Visor G. C.,
    7. Lee W. A.

    Glass vials for small parenterals: Influence of drug and manufacturing process on glass delamination. Pharm. Dev. Technol. 2001, 6 (3), 393–405.

    OpenUrlPubMed
15. 15.↵
    1. Hirakura Y.,
    2. Nakamura M.,
    3. Wakasawa T.,
    4. Ban K.,
    5. Yokota S.,
    6. Kitamura S.

    Excipient hydrolysis and ester formation increase pH in a parenteral solution over aging. Int. J. Pharm. 2006, 325 (1-2), 26–38.

    OpenUrlPubMed
16. 16.↵
    Food and Drug Administration. Safety Assessment of di(2-ethylhexyl)phthalate (DEHP) Released from PVC Medical Devices. Center for Device and Radiological Health: Rockville, MD, 2001.
17. 17.↵
    1. Meyer B. K.,
    2. Vargas D.

    Impact of tubing material on the failure of product-specific bubble points of sterilizing-grade filters. PDA J. Pharm. Sci. Technol. 2006, 60 (4), 248-253.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Akamatsu Y.

    Water-repellent coating on glass. New Glass 2006, 21,(3) 27–34.

    OpenUrl
19. 19.↵
    1. Emory S. F.

    Principles of integrity-testing hydrophilic microporous membrane filters, Part 1. Pharm. Technol. 1989, 13 (9), 68–77.

    OpenUrl